Iveric Bio announces FDA approval for IZERVAY™️️
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details
Co-founder and principal Dan Littlefield spoke on Modality Solutions’ involvement in the Ebola clinical trials with Executive Platforms for its popular EP Thought Leader Series. Most recently Dan worked with the NIH to help fight Ebola in the Democratic Republic of Congo.
Dan talks about some of the challenges of working in a conflict environment, and how Modality Solutions’ experience designing and implementing cold chain solutions to assure patient safety and drug efficacy contributed to the success of the Ebola virus clinical trial. “Our work in the Congo, along with our earlier work in Sierra Leone, Liberia, and Guinea, has been effective in ensuring clinical trial successes by applying effective engineering tools to daunting logistical problems. We’ve been fortunate to work with many great people in our efforts,” said Dan Littlefield.
You can watch the interview below:
Source: https://epthoughtleaders.com/engineering-cold-chain-solutions-to-support-ebola-clinical-trials-a-conversation-with-dan-littlefield-of-modality-solutions/
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read DetailsCongratulations to Incyte on their FDA approval for Zynyz™, a treatment for adults with metastatic...
read DetailsCongratulations to Amicus Therapeutics for their European Commission approval for Pombiliti™ in patients with Late-Onset...
read Details